43 results about "Anti ulcerogenic" patented technology

A proton pump inhibitor containing a compound represented by the formula (I)wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R2, R3 and R4 are the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, R5 and R6 are the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof. or a prodrug thereof is provided.

It is intended to provide preparations such as capsules containing an acid-unstable medicament (in particular, a benzimidazole compound having an antiulcer effect, etc.) at a high concentration which are prepared by using about 12% by weight or more (based on the total granules) of the acid-unstable chemical and blending a basic inorganic salt therewith to give granules of about 600 μm or more in the average particle size.

The invention belongs to the scientific and technical field of oral medicine and oral health, and particularly relates to an oral health-care agent capable of clearing away heat and toxic materials, and a preparation method thereof. The oral health-care agent contains a food-grade heat-clearing and detoxicating prescription, an anti-ulcer agent, a caries-prevention agent, a cell adhesion moisturizer, a natural antibacterial and anti-inflammatory agent and an oral health-care agent, preferably, the preparation further contains a preservative, more preferably, the preparation further contains apreparation-acceptable safety carrier or excipients; and all the ingredients are scientifically prepared and optimized to obtain a group of safety and multi-effect compositions which not only can clear away heat and toxic materials and is antibacterial and anti-inflammatory, but also can prevent tooth and periodontium and other oral diseases, and then a convenient and practical oral health-care agent is prepared by adopting a mild technological method. The oral health-care agent capable of clearing away heat and toxic materials not only has medicine efficacy, but also has the safety of health-care food, and is convenient to use, good in efficacy and fast in effect.

Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritatioin effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.

The present invention provides a compound having a superior acid secretion inhibitory action, an antiulcer activity and the like.A proton pump inhibitor containing a compound represented by the formula (I)wherein ring A is a saturated or unsaturated 5- or 6-membered ring group optionally having, as a ring-constituting atom besides carbon atom, 1 to 4 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, ring-constituting atoms X1 and X2 are each a carbon atom or a nitrogen atom, a ring-constituting atom X3 is a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, R1 is an optionally substituted aryl group or an optionally substituted heteroaryl group, R2 is an optionally substituted alkyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group, R3 is an aminomethyl group optionally substituted by 1 or 2 lower alkyl groups, which is a substituent on a ring-constituting atom other than X1, X2 and X3, and ring A optionally further has substituent(s) selected from a lower alkyl group, a halogen atom, a cyano group and an oxo group, or a salt thereof or a prodrug thereof.

This invention provides a solid preparation without enteric coating which contains an acid labile active ingredient, particularly, a benzimidazole compound having an antiulcer action, and can neutralize the acid in stomach quickly, and exerts quickly the pharmacological effect of the active ingredient and suppresses the generation of a carbon dioxide gas as much as possible. A gastric disintegrable solid preparation contains an acid labile active ingredient, particularly, a benzimidazole compound, and at least one component selected from metal oxides and metal hydroxides. The preparation does not enteric-coated, but has a disintegration time of 7 minutes or less.

The present invention provides acetone complexes of sulfoxide compounds, useful as medicines such as inhibitors of gastric acid secretion and anti-ulcer agents or as intermediates for production of medicines, a process for producing the same and a purification method of using the same.Namely, it is the acetone complexes of sulfoxide compounds or of pharmaceutically acceptable salts thereof represented by the following formula:(wherein R1 represents a hydrogen atom, a methoxy group or a difluoromethoxy group, R2 represents a methyl group or a methoxy group, R3 represents a 3-methoxypropoxy group, a methoxy group or a 2,2,2-trifluoroethoxy group, R4represents a hydrogen atom or a methyl group, n and m independently represent an integer of 1 to 4, and B represents a hydrogen atom, an alkali metal atom or ½ alkaline earth metal atom), which are obtained by treating the sulfoxide compounds or pharmaceutically acceptable salts thereof with acetone.

The invention provides a preparation method for a degreased periplaneta americana linnaeus extract. The preparation method comprises the following steps: (1) killing and grinding; (2) degreasing; (3)extracting; (4) concentration under reduce pressure; (5) degreasing and filtering; (6) macroporous adsorption resin column chromatography; (7) concentration under reduce pressure. According to the degreased periplaneta americana linnaeus extract prepared by the preparation method, ineffective components such as grease, polysaccharide and macromolecular protein are effectively removed, polypeptidecomponents with good anti-ulcer activity in periplaneta americana Linnaeus are enriched, the content of the polypeptide component reaches 85% or more; and the obtained degreased periplaneta americanalinnaeus extract has light color and is odor-free.

The present invention provides a method for creating rat acetic acid gastric ulcer recurrence model. Said method includes the following steps: creating rat acetic acid gastric ulcer and ulcer natural healing model, and using aspirin to induce the naturally-heated ulcer to be recurred, measuring the change of physiological and biochemical indexes in the process of rat ulcer recurrence so as to confirm that the recurrence model of gastric ulcer is created. Said model not only can be used in the research of clinical peptic ulcer recurrence mechanism, but also can be used for screening the medicines for clinically curing peptic ulcer and medicines for resisting ulcer recurrence.

The invention relates to a preparing method and anti-ulcer application of nothopanax plant extracts and a pharmaceutical composition thereof, and belongs to the field of the pharmacy of traditional Chinese medicines and natural medicines. The preparing method of an anti-ulcer medicine with the extracts as active components includes the steps of drying leaves or all of a nothopanax plant, smashingthe leaves or all of the nothopanax plant into 30 mesh, and conducting extraction with an organic solvent (chloroform or ethyl acetate or acetone or methyl alcohol or ethyl alcohol) or water. In the application of the nothopanax plant extracts to preparing an anti-ulcer agent, 0.01-30 g of nothopanax plant extracts are applied to a base material or a population and optionally combined with a carrier and / or a medium, and the good anti-ulcer activity is realized. The adaptation diseases of the nothopanax plant medicine are expanded, and the medicinal value of the nothopanax plant is improved.

The invention provides a novel herbal synergistic formulation for treatment of acute and chronic ulcers in stomach. Formulation(s) comprises of plant extracts together with the conventional additives to form the oral dosage forms which include tablets, capsules and powders ready for suspension. Utleria solicifolia along with this plants used traditionally like Asparagus racemosus, Foeniculum vulgare, and Ficus glomerata are added which are used in intestinal discomforts and as an galactogogue.

The invention discloses a salicylic acid berberine type alkaloid quaternary ammonium salt compound represented by a general formula I, a preparation method, a solubility characteristic and a pharmaceutical composition thereof, and application of the salicylic acid berberine type alkaloid quaternary ammonium salt compound in preparation of medicinal products. According to the invention, the salicylic acid berberine type alkaloid quaternary ammonium salt compound represented by the general formula I can be prepared by an organic synthesis method, shows obvious alcohol-water mixed solvent solubility, can be conveniently prepared on a large scale, has remarkable ulcerative colitis resisting activity, has the characteristics of no toxicity or low toxicity, and can be used for preventing, relieving and / or treating ulcerative colitis.

The invention relates to application of Extzw in preparation of anti-ulcerative colitis drugs for a digestive tract. The extract is a supernatant and precipitate obtained by water extraction and alcohol precipitation of Balanophora involucrata. After the supernatant is decompressed to recovery ethanol, an extract of an ethyl acetate portion and an extract of an n-butanol portion are separately obtained by extracting ethyl acetate and n-butanol sequentially, and the precipitate is washed and dried by alcohol to obtain an extract of a water extraction and alcohol precipitation portion. The Extzwand the extracts of the ethyl acetate portion and the water extraction and alcohol precipitation portion prepared from the Extzw have obvious improvement on dextran sulfate sodium (DSS)-induced ulcerative colitis in mice, can be applied to the preparation of the anti-ulcerative colitis drugs for the digestive tract, and even to the preparation of other drugs for the treatment of intestinal inflammatory diseases.

The Convolvulus extract for treating peptic ulcer and Helicobacter pylori infection is an ethanolic extract from C. pilosellifolius. The extract is prepared by homogenizing Convolvulus pilosellifolius aerial plant parts to prepare a powder, percolating the powder with an organic solvent to prepare a suspension, filtering the suspension to obtain a filtrate, and obtaining the extract as a dry powder by drying the solvent under reduced pressure from the filtrate. The active ingredient in the extract is a compound that was isolated from the extract of C. pilosellifolius as a purified triterpene using silica gel column chromatography, the compound being named: 2-propoxyethyl 13-(4-ethoxy-4-oxobutyl)-6b,8a12b,14a-tetramethyl-5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,14a-tetradecahydropicene-2-carboxylate. Both the extract and the isolated active ingredient exhibit anti-ulcerogenic activity, and disk diffusion tests show that various strains of H. pylori are susceptible to both the extract and the active ingredient.

A compound, carboxymethylchitasan bismuth zink potassium [(C12H16O8N2R2Zn)m(C12H20O8N2R2)n], for treating digestive ulcer, protecting mucosa of stomach and sobering-up is prepared through reaction between chitosan and Zn, carboxymethylation reaction, reacting on potassium hydroxide and bismuth salt, depositing, washing, filtering, baking and pulverizing.

The invention discloses a pyridino-[1,5-a]pyridine drug and a preparation method and composition thereof and application of the pyridino-[1,5-a]pyridine drug in nursing of a skin ulcer patient, and belongs to the technical field of medicine synthesis. The technical scheme comprises the key points that the pyridino-[1,5-a]pyridine drug molecule has a following molecular structure. The invention also specifically discloses the preparation method of the pyridino-[1,5-a]pyridine drug for skin ulcer care and the application in preparation of the pharmaceutical composition for skin ulcer care. By combining a thiazepine compound which has the advantages of sedation, promotion of growth hormone secretion, anti-ulcer, sterilization and the like, the pyridino-[1,5-a]pyridine drug molecule for skin ulcer care is synthesized, antibacterial activity tests are carried out, and it is showed that the compound had good inhibitory activity against Staphylococcus epidermidis and Staphylococcus aureus which easily give rise to skin ulcer.

The invention provides a traditional Chinese patent medicine for treating peptic ulcer disease. The medicine is prepared from the following traditional Chinese herbal raw materials in parts by weight: 90-150 parts of cinnamon, 80-150 parts of galangal, 50-100 parts of cuttlebone, 80-150 parts of malt, 50-100 parts of bletilla striata, 40-80 parts of golden thread, 30-70 parts of pseudo-ginseng, 40-80 parts of rhizoma atractylodis, 40-80 parts of costusroot, 50-100 parts of radix ophiopogonis, 50-100 parts of sculellaria barbata and 50-100 parts of liquidambar formosana hance. Clinical pharmacodynamic tests prove that the traditional Chinese content medicine has the remarkable effects of resisting ulcer, inhibiting gastric acid, protecting gastric mucosa, stopping bleeding and relieving pain, toxicological test results indicate that the traditional Chinese patent medicine is low in toxicity, is safe for long-time application in a clinically specified dosage range, and is a safe and effective drug for treating peptic ulcer disease. The traditional Chinese patent medicine for treating epigastralgia cold-heat jumbled peptic ulcer disease has the effects of warming spleen and kidneys, dispelling cold, regulating middle warmer, inhibiting acid, relieving pain, and removing stasis to stop bleeding.

The invention belongs to the technical field of medicines, mainly relates to a (R)-2-[[[3-methyl-4-(2,2,2-trifluoro ethoxy)-2-pyridyl) methyl] sulfinyl]-1 H-benzimidazole compound with stabile physical and chemical properties, and relates to an optically active sulfoxide compound with anti ulcer effect and a preparation method thereof, and by the embodiment of the invention, the stability is greatly improved, compared with compounds obtained by methoda in the prior art, the (R)-2-[[[3-methyl-4-(2,2,2-trifluoro ethoxy)-2-pyridyl) methyl] sulfinyl]-1 H-benzimidazole compound has especially good preservation of stability and physical properties. The compounds obtained the crystal preparation method shows excellent anti ulcer activity, gastric acid secretion inhibition effect, mucosal protective effect, anti-helicobacter pylori effect and the like.

Disclosed is the use of compounds obtained from roots, stem, bark and leaves extracts from plant species of genus Arrabidaea, in particular Arrabidaea brachypoda, also known in Brazil under the names “cipó-una” or “cervejinha do campo”, to treat ulcerogenic diseases.

A method for preparing a tree peony anti-ulcer health drink, which relates to the field of health drinks, uses tree peony, American ginseng, sealwort, licorice, fresh milk, dried peony petals, soybeans and mangoes as raw materials, firstly American ginseng, sealwort and licorice, After cleaning, crush, boil, and concentrate to obtain a concentrated liquid; remove the core of the mango and cut into pieces, squeeze and filter to obtain mango juice; add water to the soybean and boil it, then add the dried peony petals, continue cooking, and filter to obtain filtrate B Roast and pulverize the obtained peony cortex, add white wine and steam it in a steamer, place it at room temperature and add the mixed solution to filtrate B, boil and filter to obtain filtrate C; the obtained concentrated solution, mango Juice and filtrate C are evenly mixed and then sterilized, then sterilized milk is added to obtain a mixed solution, and after seasoning, it is the Moutan Cortex anti-ulcer health drink. In the preparation method of the cortex moutan anti-ulcer health care drink of the present invention, the active ingredients in each raw material act synergistically in an appropriate ratio to achieve the effects of strengthening the body and anti-ulcer.

The present invention relates to the preparation method of the effective substance group with anti-ulcerative colitis activity obtained from Guangdong Zizhu and its compound extract, and the application of the drug in the preparation of drugs for the treatment of immune inflammation. The core separation technology obtains effective substance groups for the preparation and treatment of immune inflammation including ulcerative colitis.

The invention belongs to the technical field of medicine, and relates to a voucapane-type diterpene derivative and a preparation method and application thereof. The structure of the derivative is as follows: wherein, the A / B ring is trans-parallel combined; the C ring is a benzene ring; R 1 , R 2 , R 3 , R 7 and R 8 is any one or more of H, OH, OAc, =O, and one or more of esters derived from -OH at the corresponding position; R 6 is H or OH; R 4 , R 5 and R 9 for‑CH 3 , ‑CH 2 Any one or more of OH, ‑COOH, ‑CHO, and ‑CH in the corresponding position 2 One or more of OH and -COOH derived esters. The wokaparaane-type diterpenes and pharmaceutically acceptable salts, isomers or pharmaceutical compositions thereof have immunomodulatory and anti-inflammatory effects, and can be used for preparing immunomodulators or anti-inflammatory drugs, especially anti-inflammatory drugs. Ulcerative colitis medication.

Provision of a compound having a superior proton pump action, which shows an antiulcer activity and the like after conversion to an in vivo proton pump inhibitor, a production method thereof and use thereof. A pyrrolo[2,3-c]pyridine compound represented by the formula: wherein each symbol is as defined in the specification.

The present invention relates to flavonoids isolated from Euphorbia cuneata, a method for their isolation, extracts from Euphorbia cuneata and a pharmaceutical composition comprising the flavonoids or the extracts or both of them for a use as anti-ulcer agent.

The invention discloses schisandra chinensis powder capsulate and a preparation method thereof. The capsulate consists of the schisandra chinensis powder and the auxiliary material. The weight percentages of the components are: 40 percent to 77 percent of the schisandra chinensis powder and 60 percent to 23 percent of the auxiliary material. The auxiliary material consists of calcium phosphate dibasic and micro-silica gel, the weight ratio of which is 1.5 to 4: 0.5 to 2. The product of the invention is brown, contains the natural component in the raw material and improves the schisandra chinensis lignanoid content. Taking the products can reach the goals of antitussive and expectorant effects, decreasing transaminase, expanding blood vessel, regulating the energy metabolism of myocardial cell, regulating immunity, sedation effect, anti-ulcer and anti-aging. The schisandra chinensis powder capsulate can be conserved for a long time without deterioration, the preparation method of which is simple, thereby can be easy to applied to the large scale industry production.

The invention discloses a pharmaceutical formulation for treating gastric ulcer and a preparation method of the pharmaceutical formulation. The pharmaceutical formulation comprises main materials of 4 parts of radix tinosporae and 1 part of Chinese olive, and comprises agents of ethanol, methanol, a standard substance of palmatine hydrochloride, and a standard substance of gallic acid. The preparation method comprises: extraction of active ingredients of radix tinosporae and Chinese olive, measurement of the content of the active ingredients of radix tinosporae and Chinese olive, preparation of a solution of a reference substance, exploration of a linear relation, and preparation of a test solution. In comparison with a medicine for treating related diseases in the prior art, the pharmaceutical formulation is relatively pure, is accurate in curative effect and short in course of treatment, and has no toxic or side effect. In comparison with the prior art, the preparation method takes 70% of ethanol as an extraction solvent, has no toxic effect on the body, is low in cost, and is suitable for industrial mass production. The main anti-ulcer component of palmatine hydrochloride in radix tinosporae is subjected to optimization of an extraction process and quantitative analysis through high performance liquid chromatography. The pharmaceutical formulation and the preparation method provide a theoretical reference for promoting development and utilization of radix tinosporae, and have promotion and application value.

Anti-ulcerative colitis compounds include quinazoline derivatives having the following structural formula:wherein R is H, OH, or OCH3, R1 is OH or OCH3, and R2 is OCH3 or a pharmaceutically acceptable salt thereof.

Orally administrable acid stable anti-ulcer benzimidazole derivatives which are polymer based. The process of preparation comprises condensing a benzimidazole with a biocompatible partially orally biodegradable synthetic cross linked polymer in aqueous medium at 5°-80° C. and pH 4-11 under inert atmosphere. The weight percentage of benzimidazole with respect to the polymeric benzimidazole is 1-50. The reaction mixture is cooled and the product is isolated and dried at 25°-45° C. There is also provided a formulation of the polymeric benzimidazoles in combination with pharmaceutically acceptable excipients.